If you liked this article you might like

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included
Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers